Skip to main content
Premium Trial:

Request an Annual Quote

CAT Posts Narrowed Revenue, Widened Loss in Q1

NEW YORK, Feb. 25 - Cambridge Antibody Technology on Monday reported significantly widened loss in its first quarter 2002 atop slightly thinned revenue.

 

For the period ended Dec. 31, CAT said that total revenue came to £1.9 million, or roughly $2.7 million, compared with £2.0 million one year ago.

R&D spending in the quarter, which reached £6.1 million compared with £4.7 million one year ago, led total operating costs of £7.7 million, compared with £6.3 million one year ago, CAT said.

 

As a result, the company posted a nearly doubled net, which it said was £4.0 million in the current quarter compared with £1.9 million year over year.

 

Earlier on Monday, CAT said that it had hired Peter Chambre, Celera's former chief operating officer, to replace David Chiswell as CEO. He is slated to start sometime in April.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.